NCT04454177 (SMART TAVR) is a clinical trial of HUAWEI watch in Aortic Stenosis, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT04454177?

NCT04454177 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT04454177?

Interventions in NCT04454177: HUAWEI watch.

What condition does NCT04454177 study?

NCT04454177 studies Aortic Stenosis, Valvular Heart Disease, Transcatheter Aortic Valve Replacement.

Is NCT04454177 still recruiting?

NCT04454177 is currently recruiting now. Last updated 27 October 2020.

Last reviewed 2020-10-27 · How we verify

NCT04454177: SMART TAVR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SMART Watch Facilitated Early Discharge in Patients Undergoing Transcatheter Aortic Valve Replacement

Recruiting now Last updated 27 October 2020

What this trial tests

trial testing HUAWEI watch in Aortic Stenosis in 100 participants. Currently enrolling.

Timeline

15 July 2020

Primary endpoint
31 August 2021

1 July 2031

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	100
Start date	15 July 2020
Primary completion	31 August 2021
Estimated completion	1 July 2031
Sites	1 location across China

Drugs / interventions tested

HUAWEI watch

Conditions studied

Aortic Stenosis — all drugs for Aortic Stenosis →
Valvular Heart Disease — all drugs for Valvular Heart Disease →
Transcatheter Aortic Valve Replacement — all drugs for Transcatheter Aortic Valve Replacement →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

18 and older, any sex, with Aortic Stenosis or Valvular Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to observe conduction disturbance, daily activity level, heart rates, oxygen saturation in patients who underwent Transcatheter Aortic Valve Replacement (TAVR) and to evaluate the utility of the HUAWEI Watch (HUAWEI Technologies Co., Ltd., Shenzhen, China) for the potential early warning sign of changes in multiple biometric parameters including heart rate, rhythm, oxygen saturation, activity, and sleep in patients following TAVR. This will be evaluated in the context of a recently implemented early discharge protocol.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Wearable Smartwatch Facilitated Remote Health Management for Patients Undergoing Transcatheter Aortic Valve Replacement.
Liu X, Fan J, Guo Y, Dai H, et al · · 2022 · cited 24× · PMID 35347997 · DOI 10.1161/jaha.121.023219
Unmet Needs in TAVR: Conduction Disturbances and Management of Coronary Artery Disease.
Auffret V, Ridard C, Salerno N, Sorrentino S. · · 2022 · cited 7× · PMID 36362484 · DOI 10.3390/jcm11216256
Smartwatch-Detected Arrhythmias in Patients After Transcatheter Aortic Valve Replacement (TAVR): Analysis of the SMART TAVR Trial.
Fan J, Dai H, Guo Y, Xu J, et al · · 2024 · cited 5× · PMID 39028996 · DOI 10.2196/41843
Daily Physical Activity Measured by Wearable Smartwatch for Patients Undergoing Transcatheter Aortic Valve Replacement: Insights From the SMART TAVR Study.
Fan J, Liu Q, Dai H, Zhou D, et al · · 2024 · cited 5× · PMID 38088154 · DOI 10.1161/circoutcomes.123.010066
Smartwatch detected high-degree atrioventricular block requiring pacemaker implantation after transcatheter aortic valve replacement during COVID-19.
Fan J, Liu X, Xu Y, Xu J, et al · · 2021 · cited 3× · PMID 36713599 · DOI 10.1093/ehjdh/ztab051
Myocardial infarction detected by a smartwatch after transcatheter aortic valve replacement during the COVID-19 pandemic.
Liu XB, Fan JQ, Xu YM, Guo YC, et al · · 2021 · cited 2× · PMID 34141046 · DOI 10.5847/wjem.j.1920-8642.2021.03.018
Insights into calcific aortic valve stenosis: a comprehensive overview of the disease and advancing treatment strategies
Jain H, Goyal A, Khan A, Khan N, et al · · 2024
Wearable smartwatch monitoring arrhythmias for patients who at high risk of pacemaker implantation after transcatheter aortic valve replacement.
Aihemaiti A, Fan J, Yidilisi A, Liu X, et al · · 2023 · PMID 38045441 · DOI 10.1093/ehjdh/ztad060

Verify or expand the search:

Other recruiting trials for Aortic Stenosis

Currently open trials in the same condition.

NCT07197736 — DELINEATE-Prospective · recruiting
NCT07230964 — Correlation Between an Impedance Cardiography Test for Decompensation and the Development of Left Ventricular Replacemen · NA · recruiting
NCT07205068 — Improved Outcomes With Pre-Procedure Shockwave IVL of Common Femoral Artery Access Site Prior to Large Bore Access and P · NA · recruiting
NCT07052071 — Impact of Transcatheter Aortic Valve Implantation (TAVI) on the Gut Microbiota in Patients With Aortic Valve Stenosis · recruiting
NCT07144189 — AI Assessment of Low-Gradient Aortic Stenosis Severity Based on Echocardiography · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04454177 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 27 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04454177.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing